Transgender and nonbinary (TGNB) individuals face significant discrimination and social marginalization that also translate to difficulties in health care accessibility. This review aims to summarize current barriers and identify knowledge gaps in TGNB gender-affirming surgical health care using Penchansky and Thomas's dimensions of access to care.
Methods:
A systematic review was performed via a search of the Ovid Medline, Scopus, and Web of Science databases for English peer-reviewed articles reporting original quantitative and/or qualitative data on or before April 2022.
Results:
The search retrieved 1046 total articles. Two independent reviewers screened the article titles and abstracts for relevance. Twenty-five articles met the criteria and were included in the review. Most studies were based on patient surveys, while some examined insurance policy coverage. Three major themes emerged as significant barriers to gender-affirming surgical and hormonal care: affordability, accessibility, and racial disparities. Affordability was most often related to inconsistent or inadequate insurance coverage hindering access to care. Geographic accessibility highlighted a lack of proficient providers in gender-affirming surgical and hormonal care in certain areas of the United States and in the suburban and rural settings. Lastly, racial minorities were less likely to access gender-affirming care and may be located in areas where access was limited.
Conclusions:
While overall access for TGNB patients has improved, considerable barriers remain. Penchansky and Thomas's dimensions of access to care explicate barriers in geographic accessibility to providers and procedures, affordability and insurance coverage, and racial disparities within the TGNB population. Such inequalities demand both medical and public health policy changes.
Get full access to this article
View all access options for this article.
References
1.
TranBNN, EpsteinS, SinghalD, et al.Gender affirmation surgery: A Synopsis Using American College of Surgeons National Surgery Quality Improvement Program and National Inpatient Sample Databases. Ann Plast Surg, 2018; 80(4 Suppl. 4):S229–S235; doi: 10.1097/sap.0000000000001350.
2.
CannerJK, HarfouchO, KodadekLM, et al.Temporal trends in gender-affirming surgery among transgender patients in the United States. JAMA Surg, 2018; 153(7):609–616; doi: 10.1001/jamasurg.2017.6231.
3.
NolanIT, KuhnerCJ, DyGW. Demographic and temporal trends in transgender identities and gender confirming surgery. Transl Androl Urol, 2019; 8(3):184–190; doi: 10.21037/tau.2019.04.09.
4.
MeyerG, MayerM, MondorfA, et al.Increasing normality-persisting barriers: Current socio-demographic characteristics of 350 individuals diagnosed with gender dysphoria. Clin Endocrinol (Oxf), 2020; 92(3):241–246; doi: 10.1111/cen.14140.
5.
MeerwijkEL, SeveliusJM. Transgender population size in the United States: A meta-regression of population-based probability samples. Am J Public Health, 2017; 107(2):e1–e8; doi: 10.2105/ajph.2016.303578.
6.
AlmazanAN, KeuroghlianAS. Association between gender-affirming surgeries and mental health outcomes. JAMA Surg, 2021; 156(7):611–618; doi: 10.1001/jamasurg.2021.0952.
7.
AlconA, KennedyA, WangE, et al.Quantifying the psychosocial benefits of masculinizing mastectomy in trans male patients with patient-reported outcomes: The University of California, San Francisco, Gender Quality of Life Survey. Plast Reconstr Surg, 2021; 147(5):731e–740e; doi: 10.1097/prs.0000000000007883.
8.
PoudrierG, NolanIT, CookTE, et al.Assessing quality of life and patient-reported satisfaction with masculinizing top surgery: A mixed-methods descriptive survey study. Plast Reconstr Surg, 2019; 143(1):272–279; doi: 10.1097/prs.0000000000005113.
9.
JamesSE, HermanJL, RankinS, et al.Executive Summary of the Report of the 2015 U.S. Transgender Survey. National Center for Transgender Equality: Washington, DC, USA; 2016.
10.
PageMJ, McKenzieJE, BossuytPM, et al.The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ, 2021; 372:n71; doi: 10.1136/bmj.n71.
11.
MoherD, LiberatiA, TetzlaffJ, et al.Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLoS Med, 2009; 6(7):e1000097; doi: 10.1371/journal.pmed.1000097.
12.
ArkseyH, O'MalleyL. Scoping studies: Towards a methodological framework. Int J Soc Res Methodol, 2005; 8(1):19–32; doi: 10.1080/1364557032000119616.
13.
O'NeillJ, TabishH, WelchV, et al.Applying an equity lens to interventions: Using PROGRESS ensures consideration of socially stratifying factors to illuminate inequities in health. J Clin Epidemiol, 2014; 67(1):56–64; doi: 10.1016/j.jclinepi.2013.08.005.
14.
PenchanskyR, ThomasJW. The concept of access: Definition and relationship to consumer satisfaction. Med Care, 1981; 19(2):127–140; doi: 10.1097/00005650-198102000-00001.
15.
SaurmanE. Improving access: Modifying Penchansky and Thomas's Theory of Access. J Health Serv Res Policy, 2015; 21(1):36–39; doi: 10.1177/1355819615600001.
16.
GarciaJ, CrosbyRA. Social determinants of discrimination and access to health care among transgender women in Oregon. Transgend Health, 2020; 5(4):225–233; doi: 10.1089/trgh.2019.0090.
17.
DagiAF, BoskeyER, NuzziLC, et al.Legislation, market size, and access to gender-affirming genital surgery in the United States. Plast Reconstr Surg Glob Open, 2021; 9(2):e3422; doi: 10.1097/gox.0000000000003422.
18.
BakkoM, KattariSK. Transgender-related insurance denials as barriers to transgender healthcare: Differences in experience by insurance type. J Gen Intern Med, 2020; 35(6):1693–1700; doi: 10.1007/s11606-020-05724-2.
19.
ZaliznyakM, JungEE, BreseeC, et al.Which U.S. States' Medicaid Programs provide coverage for gender-affirming hormone therapy and gender-affirming genital surgery for transgender patients?: A state-by-state review, and a study detailing the patient experience to confirm coverage of services. J Sex Med, 2021; 18(2):410–422; doi: 10.1016/j.jsxm.2020.11.016.
20.
AlmazanAN, BensonTA, BoskeyER, et al.Associations between transgender exclusion prohibitions and insurance coverage of gender-affirming surgery. LGBT Health, 2020; 7(5):254–263; doi: 10.1089/lgbt.2019.0212.
21.
NgaageLM, KnightonBJ, BenzelCA, et al.A review of insurance coverage of gender-affirming genital surgery. Plast Reconstr Surg, 2020; 145(3):803–812; doi: 10.1097/prs.0000000000006591.
22.
KirklandA, TaleshS, PeroneAK. Transition coverage and clarity in self-insured corporate health insurance benefit plans. Transgend Health, 2021; 6(4):207–216; doi: 10.1089/trgh.2020.0067.
23.
ScheimAI, ColemanT, LachowskyN, et al.Health care access among transgender and nonbinary people in Canada, 2019: A cross-sectional survey. CMAJ Open, 2021; 9(4):E1213–E1222; doi: 10.9778/cmajo.20210061.
24.
SineathRC, WoodyattC, SanchezT, et al.Determinants of and barriers to hormonal and surgical treatment receipt among transgender people. Transgend Health, 2016; 1(1):129–136; doi: 10.1089/trgh.2016.0013.
25.
OliphantJ, BarnettD, VealeJ, et al.The wellbeing and health needs of a cohort of transgender young people accessing specialist medical gender-affirming healthcare in Auckland. N Z Med J, 2021; 134(1541):33–44.
26.
JarrettBA, PeitzmeierSM, RestarA, et al.Gender-affirming care, mental health, and economic stability in the time of COVID-19: A multi-national, cross-sectional study of transgender and nonbinary people. PLoS One, 2021; 16(7):e0254215; doi: 10.1371/journal.pone.0254215.
27.
de HaanG, SantosGM, ArayasirikulS, et al.Non-prescribed hormone use and barriers to care for transgender women in San Francisco. LGBT Health, 2015; 2(4):313–323; doi: 10.1089/lgbt.2014.0128.
28.
WilsonEC, ChenYH, ArayasirikulS, et al.Connecting the dots: Examining transgender women's utilization of transition-related medical care and associations with mental health, substance use, and HIV. J Urban Health, 2015; 92(1):182–192; doi: 10.1007/s11524-014-9921-4.
29.
BrownGR, JonesKT. Racial health disparities in a cohort of 5,135 transgender veterans. J Racial Ethn Health Disparities, 2014; 1(4):257–266; doi: 10.1007/s40615-014-0032-4.
30.
NolanIT, PoudrierG, MotoskoCC, et al.Continued barriers to top surgery among transgender men. Plast Reconstr Surg, 2020; 145(2):464e–465e; doi: 10.1097/prs.0000000000006487.
31.
FaletskyA, HanJJ, LeeKJ, et al.Crowdfunding for gender-affirming mastectomy: Balancing fundraising with loss of privacy. Ann Plast Surg, 2022; 88(4):372–374; doi: 10.1097/sap.0000000000002953.
32.
GonzalesG, Henning-SmithC. Barriers to care among transgender and gender nonconforming adults. Milbank Q, 2017; 95(4):726–748.
33.
CohenWA, SangalangAM, DalenaMM, et al.Navigating insurance policies in the United States for gender-affirming surgery. Plast Reconstr Surg Glob Open, 2019; 7(12):e2564; doi: 10.1097/gox.0000000000002564.
34.
GadkareeSK, DeVoreEK, RichburgK, et al.National Variation of Insurance Coverage for gender-affirming facial feminization surgery. Facial Plast Surg Aesthet Med, 2021; 23(4):270–277; doi: 10.1089/fpsam.2020.0226.
35.
BrethertonI, ThrowerE, ZwicklS, et al.The health and well-being of transgender Australians: A National Community Survey. LGBT Health, 2021; 8(1):42–49; doi: 10.1089/lgbt.2020.0178.
36.
KerA, ShawRM, ByrneJ, et al.Access to fertility preservation for trans and non-binary people in Aotearoa New Zealand. Cult Health Sex, 2022; 24(9):1273–1288; doi: 10.1080/13691058.2021.1944670.
